Latest Breaking News On - Arbutus biopharma corporation nasdaq - Page 1 : comparemela.com

Arbutus to Participate in Jefferies Global Healthcare Conference

29.05.2024 - WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B .

Lisam caperelliArbutus biopharma corporation nasdaqBiopharma corporation

Arbutus to Present Imdusiran Data at EASL Congress 2024

WARMINSTER, Pa., May 22, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.

United statesN acetylgalactosamine galnacKosh agarwalFung yuenLisam caperelliArbutus biopharma corporation nasdaqSecurities exchangeWorld health organizationBiopharma corporationEuropean associationPoster tourLooking statementsSecurities actSecurities exchange actArbutu annual reportArbutu quarterly reports

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus to Participate in Two Upcoming Investor Conferences
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Lisam caperelliArbutus biopharma corporation nasdaqBiopharma corporation

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.

United statesKatie andersonRam bhamidimarriRonaldg nahassDeana antonielloKosh agarwalAnita kohliJeong heoGavin clohertyLouise busseyNaim alkhouriShariec ganchuaStuartc gordonChristinel espirituTatiana burdaStuart roberts

Arbutus Announces Retirement of Chief Scientific Officer, Michael J Sofia, PhD, Effective December 31, 2024

WARMINSTER, Pa., May 02, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.

Michaelj mcelhaughLisam caperelliSecurities exchangeArbutus biopharma corporation nasdaqBiopharma corporationChief scientific officerMichael sofiaInterim presidentChief executive officerLooking statementsSecurities actSecurities exchange actArbutu annual reportArbutu quarterly reports